Clinical trials
Terminated Phase 2 Leukemia, Myelomonocytic, Chronic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 5 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2017 | 2 |
| 2018 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 26 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 3 |
| Fred Hutchinson Cancer Center | 2 |
| National Cancer Institute (NCI) | 2 |
| Northside Hospital, Inc. | 2 |
| OHSU Knight Cancer Institute | 2 |
| Wake Forest University Health Sciences | 2 |
| Alison Walker | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| CTI BioPharma | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelomonocytic, Chronic | 26 |
| Myelodysplastic Syndromes | 19 |
| Leukemia, Myeloid, Acute | 14 |
| Leukemia | 13 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 11 |
| Myeloproliferative Disorders | 10 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 |
| Multiple Myeloma | 9 |
| Primary Myelofibrosis | 9 |
| Anemia, Refractory, with Excess of Blasts | 8 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.